-- Moderna（MRNA）周五宣布，其癌症疗法mRNA-4359的早期临床试验数据显示，总体缓解率高达83%，增强了人们对该疗法潜力的信心。 该疗法正与免疫疗法药物帕博利珠单抗（pembrolizumab）联合使用，作为晚期或转移性黑色素瘤患者的一线治疗方案进行评估。帕博利珠单抗是一种用于治疗多种癌症的免疫疗法药物。 该公司表示，美国食品药品监督管理局（FDA）已授予该联合疗法针对特定晚期黑色素瘤患者的快速通道资格，这有望加快其研发和监管审批进程。 Moderna将于4月17日至22日举行的美国癌症研究协会（AACR）年会上公布该1/2期临床试验的结果。
Price: $54.50, Change: $-0.18, Percent Change: -0.33%
Huaqin Technology (HKG:3296, SHA:603296) set the offer price for its Hong Kong initial public offering at HK$77.70 per share, according to a Tuesday Hong Kong bourse filing.The China-based smart hardware products manufacturer is offering 58.5 million Hong Kong-listed shares, seeking to raise up to about HK$4.55 billion from the deal.The company expects to announce the results of the international offering and the Hong Kong public offering, along with allocation details, on Wednesday.Trading in the shares is scheduled to begin on Thursday, with shares to be traded in board lots of 100.
CITIC Metal's (SHA:601061) net profit attributable to shareholders in the first quarter soared 141% year on year to 1.38 billion yuan, or 0.28 yuan per share, according to a Shanghai bourse filing on Wednesday.Operating revenue jumped 53% to 43.2 billion yuan from 28.2 billion yuan in the previous year.The Chinese iron ore company's shares surged 10% in the morning trade.
Tokyo Electric Power (TYO:9501) (TEPCO) said it received 4.7 billion yen in grants from the Nuclear Damage Compensation and Decommissioning Facilitation Corporation under a revised business plan approved in March, according to a Wednesday filing on the Tokyo Stock Exchange.The funding follows the company's latest request as compensation payments linked to the nuclear accident were set to exceed previously secured amounts by the end of May.TEPCO has received a cumulative 188.9 billion yen in indemnity payments and 11.5 trillion yen in grants from the NDF to date. The utility said the additional support will be used to continue compensation payouts to those affected by the disaster.